BE XR OD vs IR BID - which Cmax for IR? [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-05-11 06:29 (87 d 08:50 ago) – Posting: # 21417
Views: 1,310

» I would like to have the help of the forum participants on a tricky question, ie which IR Cmax should be considered to assess the potential bioequivalence between an IR formulation administered BID and an XR formulation administered OD on day 1 and at steady-state. This is for a submission to FDA.

Not sure if the following will answer your Q exactly and whether it still exists on FDA website (or they blacked out the results):
Look for Ultram ER at [email protected]
Similar approach (Don't ask how I know :))

J

Complete thread:

Activity
 Admin contact
20,969 posts in 4,374 threads, 1,460 registered users;
online 17 (1 registered, 16 guests [including 9 identified bots]).
Forum time: Thursday 15:19 CEST (Europe/Vienna)

It is a good morning exercise for a research scientist
to discard a pet hypothesis every day before breakfast.
It keeps him young.    Konrad Lorenz

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5